LungAI

What is LungAI?

LungAI is an AI-powered CADx diagnostic tool that provides a continuous 0–100 malignancy probability score for every nodule in a lung CT scan. It is designed to integrate directly into a radiologist’s existing CADe viewer, replacing manual Lung-RADS categorization with automated, data-driven risk assessment.

Key Features

• 100M-parameter Vision Transformer trained on 100,000 CT scans, achieving an AUROC of 0.96 on the NLST held-out set (vs 0.88 for Lung-RADS).
• Longitudinal tracking with automatic comparison to prior scans, reducing read time from 5–10 minutes to 1.5–3 minutes.
• Zero workflow disruption – embedded directly in the CADe viewer; no new login, workstation, or IT project required.
• Reimbursable under CPT 0721T (post-FDA clearance).

Clinical Evidence

At a high-sensitivity threshold, LungAI demonstrates 94% sensitivity and approximately 88% specificity, offering a 60–80% reduction in missed cancers and a 33% reduction in unnecessary biopsies compared to standard manual reads.

Integration

LungAI is delivered through native integration with PACS/CADe vendors, unlocking entire hospital networks with a single partnership. Post-FDA clearance, qualifying scans are eligible for reimbursement under CPT 0721T.